Nektar Therapeutics is a stage-clinical biopharmaceutical company. The Сompany develops new drug candidates by applying its proprietary PEGylation and advanced polymer conjugate technologies to modify the chemical structure of substances. It is a technology supplier to a number of pharmaceutical companies including Affymax, Amgen, Merck, Pfizer and UCB Pharma, etc. Nektar Therapeuticsэ R&D pipeline of new investigational drugs includes treatments for cancer, auto-immune disease, and chronic pain.

Employee Rating

3.7More
TypePublic
HQSan Francisco, US
Founded1990
Size (employees)509 (est)+9%
Websitenektar.com
Nektar Therapeutics was founded in 1990 and is headquartered in San Francisco, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Nektar Therapeutics

Robert Chess

Robert Chess

Chairman of the Board
Jillian Thomsen

Jillian Thomsen

Senior Vice President, Finance and Chief Accounting Officer
Dorian Hirth

Dorian Hirth

Senior Vice President, Human Resources and Facilities Operations
Timothy Riley

Timothy Riley

Senior Vice President, Technology Assessment and Quality Assurance
Show more

Nektar Therapeutics Office Locations

Nektar Therapeutics has offices in San Francisco, Huntsville and Hyderabad
San Francisco, US (HQ)
455 Mission Bay Boulevard South
Huntsville, US
1112 Church Street
Hyderabad, IN
Sy.Nos.101/2 Genome Valley Lalgadi Malakpet Shameerpet Mandal Rangareddy District Hyderabad
Show all (3)
Report incorrect company information

Nektar Therapeutics Financials and Metrics

Nektar Therapeutics Revenue

Embed Graph
Nektar Therapeutics's revenue was reported to be $307.71 m in FY, 2017
USD

Revenue (Q3, 2018)

27.8m

Gross profit (Q3, 2018)

23.0m

Gross profit margin (Q3, 2018), %

82.8%

Net income (Q3, 2018)

(96.1m)

EBIT (Q3, 2018)

(98.6m)

Market capitalization (9-Nov-2018)

5.9b

Closing stock price (9-Nov-2018)

34.0

Cash (30-Sep-2018)

222.3m
Nektar Therapeutics's current market capitalization is $5.9 b.
Annual
USDFY, 2013FY, 2014FY, 2015Y, 2015FY, 2016FY, 2017

Revenue

148.9m200.7m230.8m230.8m165.4m307.7m

Revenue growth, %

35%15%(28%)

Cost of goods sold

38.5m28.5m34.1m34.1m30.2m30.5m

Gross profit

110.4m172.2m196.7m196.7m135.2m277.2m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

60.9m19.8m28.5m132.9m108.8m22.7m60.0m58.9m32.8m36.3m24.7m34.6m152.9m38.0m1.1b27.8m

Cost of goods sold

12.9m7.9m5.1m9.2m8.4m10.5m6.8m8.9m7.7m7.0m6.1m9.0m5.7m6.6m5.5m4.8m

Gross profit

48.0m11.9m23.4m123.7m100.4m12.1m53.2m50.0m25.1m29.3m18.6m25.6m147.3m31.4m1.1b23.0m

Gross profit Margin, %

79%60%82%93%92%54%89%85%76%81%75%74%96%83%99%83%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

39.1m12.4m55.6m59.6m4.8m

Accounts Receivable

Inventories

13.5m13.0m11.3m11.1m10.7m

Current Assets

257.9m288.2m350.1m426.3m326.8m
Quarterly
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(162.0m)(53.9m)(81.2m)(153.5m)(96.7m)

Depreciation and Amortization

14.3m12.9m12.9m15.4m14.7m

Inventories

4.8m500.0k1.6m237.0k383.0k

Accounts Payable

6.2m(6.4m)(412.0k)518.0k2.1m
Quarterly
USDY, 2018

Financial Leverage

1.3 x
Show all financial metrics
Report incorrect company information

Nektar Therapeutics Online and Social Media Presence

Embed Graph
Report incorrect company information

Nektar Therapeutics News and Updates

Nektar Therapeutics Presents New Clinical and Preclinical Data for its Immuno-Oncology Pipeline at the 2018 Society for Immunotherapy of Cancer (SITC) Annual Meeting

SAN FRANCISCO, Nov. 9, 2018 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today a presentation of new clinical and preclinical data for its I-O pipeline at the 2018 Society for Immunotherapy of Cancer (SITC) Annual Meeting. New clinical study results from the PIVOT-02 Phase ...

Kessler Topaz Meltzer & Check, LLP: Securities Fraud Class Action Filed Against Nektar Therapeutics - NKTR

RADNOR, Pa., Nov. 9, 2018 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP alerts investors that a securities fraud class action lawsuit has been filed against Nektar Therapeutics (Nasdaq: NKTR) ("Nektar") on behalf of purchasers of Nektar securities between November 11, ...

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Nektar Therapeutics To Contact The Firm

NEW YORK, Nov. 8, 2018 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ:NKTR) of the December 31, 2018 deadline to seek the role of lead plaintiff in a federal securities class action ...

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Nektar Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - NKTR

NEW YORK, Nov. 7, 2018 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Nektar Therapeutics, Inc. ("Nektar" or the "Company") (NASDAQ: NKTR) and certain of its officers. The class action, filed in United States District Court, Northern District of ...

NEKTAR INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Nektar Therapeutics To Contact The Firm

NEW YORK, Nov. 2, 2018 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ:NKTR). If you invested in Nektar stock or options and would like to discuss your legal...

Nektar Therapeutics (NKTR) Investigated by Block & Leviton LLP For Violations of Federal Securities Laws

BOSTON, Oct. 3, 2018 /PRNewswire/ -- Block & Leviton LLP (www.blockesq.com), a securities litigation firm representing investors nationwide, is investigating whether Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR) and certain of its officers and directors violated federal...
Show more
Report incorrect company information

Nektar Therapeutics Blogs

Nektar Appoints Wei Lin, M.D., as Senior Vice President of Clinical Development and Head of Nektar's Oncology Programs

Nektar Appoints Wei Lin, M.D., as Senior Vice President of Clinical Development and Head of Nektar's Oncology Programs Content Import Wed, 11/14/2018 - 09:04 Nektar Appoints Wei Lin, M.D., as Senior Vice President of Clinical Development and Head of Nektar's Oncology Programs …

Nektar Therapeutics Reports Financial Results for the Third Quarter of 2018

SAN FRANCISCO , Nov. 7, 2018 /PRNewswire/ --  Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the third quarter ended September 30, 2018 . Cash and investments in marketable securities at September 30, 2018 were $2.0 billion as compared to $353.2 million at December 31,

New Clinical Oncology Collaboration Between Nektar and Pfizer to Evaluate Combination of NKTR-214, a CD122-Biased Agonist, with Avelumab and Talazoparib or Enzalutamide in Multiple Cancers

SAN FRANCISCO , Nov. 6, 2018 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) announced that it has entered into an oncology clinical collaboration with Pfizer Inc. (NYSE:PFE) to evaluate several combination regimens in multiple cancer settings, including metastatic castration-resistant prostate

Nektar Therapeutics to Host Webcast Conference Call with Melanoma Specialists for Analysts & Investors During 2018 Society for Immunotherapy of Cancer 33rd Annual Meeting

Nektar Therapeutics to Host Webcast Conference Call with Melanoma Specialists for Analysts & Investors During 2018 Society for Immunotherapy of Cancer 33rd Annual Meeting Content Import Tue, 11/06/2018 - 08:05 Nektar Therapeutics to Host Webcast Conference Call with Melanoma Specialist…

Nektar to Announce Financial Results for the Third Quarter 2018 on Wednesday, November 7, 2018, After Close of U.S.-Based Financial Markets

SAN FRANCISCO , Oct. 30, 2018 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter on Wednesday, November 7, 2018 , after the close of U.S.-based financial markets. Howard Robin , president and chief executive officer, will host a conference

Nektar Therapeutics Announces Ten Abstracts Accepted for Presentation at the 2018 Society for Immunotherapy of Cancer (SITC) Annual Meeting

SAN FRANCISCO , Oct. 2, 2018 /PRNewswire/ --  Nektar Therapeutics (Nasdaq: NKTR) today announced that ten clinical and preclinical data presentations across its immuno-oncology portfolio will be presented at the upcoming Society for Immunotherapy of Cancer ( SITC ) Annual Meeting, which is being

Nektar Therapeutics Company Life and Culture

Report incorrect company information

Nektar Therapeutics Frequently Asked Questions

  • When was Nektar Therapeutics founded?

    Nektar Therapeutics was founded in 1990.

  • Who are Nektar Therapeutics key executives?

    Nektar Therapeutics's key executives are Robert Chess, Jillian Thomsen and Dorian Hirth.

  • How many employees does Nektar Therapeutics have?

    Nektar Therapeutics has 509 employees.

  • What is Nektar Therapeutics revenue?

    Latest Nektar Therapeutics annual revenue is $307.7 m.

  • What is Nektar Therapeutics revenue per employee?

    Latest Nektar Therapeutics revenue per employee is $604.5 k.

  • Who are Nektar Therapeutics competitors?

    Competitors of Nektar Therapeutics include Northwest Biotherapeutics, Merrimack Pharmaceuticals and TESARO.

  • Where is Nektar Therapeutics headquarters?

    Nektar Therapeutics headquarters is located at 455 Mission Bay Boulevard South, San Francisco.

  • Where are Nektar Therapeutics offices?

    Nektar Therapeutics has offices in San Francisco, Huntsville and Hyderabad.

  • How many offices does Nektar Therapeutics have?

    Nektar Therapeutics has 3 offices.